Contraindicated. Coadministration of doravirine with a powerful CYP3A inducer may well reduce doravirine plasma concentrations and/or effects. Opportunity for lack of virologic reaction and possible resistance to doravirine.
pentobarbital will minimize the extent or influence of armodafinil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Not known.
pentobarbital will lower the extent or outcome of abiraterone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
pentobarbital will decrease the extent or result of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate Drug. Powerful CYP3A4 inducers are anticipated to bring about significant decreases in sildenafil plasma ranges
benzhydrocodone/acetaminophen and pentobarbital both equally boost sedation. Avoid or Use Alternate Drug. Restrict use to clients for whom substitute procedure selections are inadequate
pentobarbital will reduce the extent or result of temsirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
Monoamine oxidase inhibitors (MAOI) could inhibit barbiturate metabolism and extend barbiturate effects; keep an eye on carefully
Contraindicated (one)pentobarbital will reduce the extent or effect of lumacaftor/ivacaftor by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lower the extent or result of ritonavir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
pentobarbital will lessen the level or outcome of oliceridine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe. If coadministration with a CYP3A4 inducer is necessary, think about expanding oliceridine dose until eventually steady drug effects are achieved; observe for signs of opioid withdrawal.
Check Closely (1)pentobarbital will minimize the extent or influence of fentanyl intranasal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Check Closely. Coadministration of get more info fentanyl with CYP3A4 inducers could lead to the reduce in fentanyl plasma concentrations, lack of efficacy or, possibly, enhancement of the withdrawal syndrome in the individual who has developed Actual physical dependence to fentanyl. Soon after stopping a CYP3A4 inducer, since the effects in the inducer decline, the fentanyl plasma focus will boost which could improve or lengthen equally the therapeutic and adverse effects.
pentobarbital will lower the extent or outcome of paclitaxel protein certain by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Not known.
With therapeutic doses of TCAs, barbiturates increase metabolism and reduce blood concentrations of TCAs.
pentobarbital will reduce the level or impact of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Not known.